Skip to main content
SpringerLink
Log in

Six-Month Clinical Status as a Predictor of 24-Month Clinical Outcome in First-Admission Patients with Schizophrenia

  • Published:
Annals of Clinical Psychiatry

Abstract

The aim of this study was to determine whether clinical status at 6-month follow-up is a predictor of 2-year clinical status in first-admission schizophrenic patients. If short-term status is indeed a strong predictor of subsequent functioning, the relationship would support earlier initiation of aggressive interventions. An epidemiologically based sample of 162 first-admission schizophrenic patients was examined at index hospitalization and at 6- and 24-month follow-up, using a variety of diagnostic and clinical assessment instruments. Respondents were divided into three groups based on their 6-month clinical status: delusions or hallucinations present at 6-month follow-up with or without negative symptoms (n = 63); moderate to high levels of negative symptoms (but not positive symptoms) present (n = 42); neither positive nor negative symptoms present (n = 57). Differences in 24-month clinical functioning were evaluated (GAF scores, BPRS factors, role functioning, number of rehospitalizations, and illness course). No significant differences were found among the three groups on demographic characteristics, substance abuse history, or extent of treatment during the follow-up. At 24-month follow-up, respondents with positive psychotic symptoms at 6-month follow-up had the worst, and those with no positive or negative symptoms the best functioning, with the negative-symptom group intermediate on most indices. Thus, among schizophrenic patients, poor 6-month clinical status identified a patient subgroup at high risk for continued poor clinical status at 24 months, suggesting the need for earlier intensive intervention in an attempt to prevent this progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789–796

    Google Scholar 

  2. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151(6 suppl.):825–835

    Google Scholar 

  3. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1774–1752

    Google Scholar 

  4. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827–832

    Google Scholar 

  5. Ereshefsky L: Treatment strategies for schizophrenia. Psychiatr Ann 1995; 25:285–296

    Google Scholar 

  6. Wasylenki DA: Psychotherapy of schizophrenia revisited. Hosp Commun Psychiatry 1992; 43:123–127

    Google Scholar 

  7. Burns BJ, Santos AB: Assertive community treatment: an update of randomized trials. Psychiatr Serv 1995; 46:669–675

    Google Scholar 

  8. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150:1630–1638

    Google Scholar 

  9. Ghaemi SN, Ziegler DM, Peachey TJ, Goodwin FK: Cost-effectiveness of clozapine therapy for severe psychosis. Psychiatr Serv 1998; 49:829–831

    Google Scholar 

  10. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia [see comments]. N Engl J Med 1997; 337:809–815

    Google Scholar 

  11. Albright PS, Livingstone S, Keegan DL, Ingham M, Shrikhande S, LeLorier J: Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy—-a retrospective analysis using the Saskatchewan Health Linkable Databases. Clin Drug Invest 1996; 11:289–299

    Google Scholar 

  12. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 197; 154:1248–1254

  13. Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I: Risperidone versus haloperidol: II. cost-effectiveness. Clin Ther 1998; 20:196–213

    Google Scholar 

  14. Marder SR, Van Putten T: Who should receive clozapine? Arch Gen Psychiatry 1988 45:865–867

    Google Scholar 

  15. Hoge MA, Davidson L, Griffith EE, Sledge WH, Howenstine RA: Defining managed care in public sector psychiatry. Hosp Commun Psychiatry 1994; 45:1085–1089

    Google Scholar 

  16. Garnick DW, Hendricks AM, Dulski JD, Thorpe KE, Horgan C: Characteristics of private-sector managed care for mental health and substance abuse treatment. Hosp Commun Psychiatry 1994; 45:1201–1205

    Google Scholar 

  17. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20–26

    Google Scholar 

  18. Bromet EJ, Jandorf L, Fennig S, Lavelle J, Kovasznay B, Ram R, Tanenberg-Karant M, Craig T: Premorbid and clinical predictors of short-term course in first-admission psychotic patients: Preliminary results. Psychol Med 1996; 26:953–962

    Google Scholar 

  19. Spitzer RL, Williams J, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID) I: history, rationale and description. Arch Gen Psychiatry 1992; 49:624–629

    Google Scholar 

  20. Fennig S, Kovasznay B, Rich C, Ram R, Pato C, Miller A, Rubinstein J, Carlson G, Schwartz JE, Phelan J, Lavelle J, Craig T, Bromet E: Six-month stability of psychiatric diagnosis in first admission patients with psychosis. Am J Psychiatry 1994; 151:1200–1208

    Google Scholar 

  21. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M: Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 1995; 52:341–351

    Google Scholar 

  22. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A: Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med 1992(monograph suppl 1992); 20:1–97

    Google Scholar 

  23. Woerner MG, Mannuzza S, Kane JM: Anchoring the BPRS: an aid to improved reliability. Psychopharm Bull 1988; 24:112–117

    Google Scholar 

  24. Heinrichs DW, Hanlon TE, Carpenter WT Jr: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388–398

    Google Scholar 

  25. Marengo J, Harrow M, Sands J, Galloway C: European versus United States data on the course of schizophrenia. Am J Psychiatry 1991; 148:606–611

    Google Scholar 

  26. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409–1416

    Google Scholar 

  27. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE: The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull 1992; 18:185–201

    Google Scholar 

  28. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharm 1993; 13:25–40

    Google Scholar 

  29. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825–835

    Google Scholar 

  30. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995; 166:712–26

    Google Scholar 

  31. Keefe RSE, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL: Characteristics of very poor outcome schizophrenia. Am J Psychiatry 1987; 144:889–895

    Google Scholar 

  32. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD: Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146:905–908

    Google Scholar 

  33. Peralta V, de Leon J, Cuesta MJ: Are there more than two syndromes in schizophrenia? a critique of the positive-negative dichotomy. Br J Psychiatry 1992; 161:335–343

    Google Scholar 

  34. Yates WR, Jacoby CG, Andreasen NC: Cerebellar atrophy in schizophrenia and affective disorder. Am J Psychiatry 1987; 144:465–467

    Google Scholar 

  35. Smith JV, Birchwood MJ: Specific and non-specific effects of educational intervention with families living with a schizophrenic relative. Br J Psychiatry 1987; 150:645–652

    Google Scholar 

  36. Liddle PF: Schizophrenic syndromes, cognitive performance and neurological dysfunction. Psychol Med 1987; 17:49–57

    Google Scholar 

  37. Breier A, Schreiber JL, Dyer J, Pickar D: The National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991; 48:239–246

    Google Scholar 

  38. Harrow M, Grinker RR, Silverstein ML, Holzman P: Is modern-day schizophrenia outcome still negative? Am J Psychiatry 1978; 135:1156–1162

    Google Scholar 

  39. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50:369–376

    Google Scholar 

  40. Schooler NR: Translating treatment research findings into clinical action [editorial]. Am J Psychiatry 1994; 151:1719–1721

    Google Scholar 

  41. Harding CM, Zubin J, Strauss JS: Chronicity in schizophrenia: fact, partial fact, or artifact? Hosp Commun Psychiatry 1987; 38:477–486

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Veterans Affairs, Veterans Integrated Services Network 3, Bronx, New York

    Thomas Craig

  2. Shelvata Hospital, Tel Aviv, Israel

    Shmuel Fennig

  3. Department of Psychiatry and Behavior Sciences, State University of New York at Stony Brook, Stony Brook, New York

    Marsha Tanenberg-Karant & Evelyn J. Bromet

Authors
  1. Thomas Craig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shmuel Fennig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marsha Tanenberg-Karant
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Evelyn J. Bromet
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Craig, T., Fennig, S., Tanenberg-Karant, M. et al. Six-Month Clinical Status as a Predictor of 24-Month Clinical Outcome in First-Admission Patients with Schizophrenia. Ann Clin Psychiatry 11, 197–203 (1999). https://doi.org/10.1023/A:1022357312048

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022357312048

Search

Navigation